Metformin is considered to be one of the most effective therapeutics for treating type 2 diabetes because it specifically reduces hepatic gluconeogenesis without increasing insulin secretion, inducing weight gain or posing a risk of hypoglycaemia 1,2 . For over half a century, this agent has been prescribed to patients with type 2 diabetes worldwide, yet the underlying mechanism by which metformin inhibits hepatic gluconeogenesis remains unknown. Here we show that metformin non-competitively inhibits the redox shuttle enzyme mitochondrial glycerophosphate dehydrogenase, resulting in an altered hepatocellular redox state, reduced conversion of lactate and glycerol to glucose, and decreased hepatic gluconeogenesis. Acute and chronic low-dose metformin treatment effectively reduced endogenous glucose production, while increasing cytosolic redox and decreasing mitochondrial redox states. Antisense oligonucleotide knockdown of hepatic mitochondrial glycerophosphate dehydrogenase in rats resulted in a phenotype akin to chronic metformin treatment, and abrogated metformin-mediated increases in cytosolic redox state, decreases in plasma glucose concentrations, and inhibition of endogenous glucose production. These findings were replicated in whole-body mitochondrial glycerophosphate dehydrogenase knockout mice. These results have significant implications for understanding the mechanism of metformin's blood glucose lowering effects and provide a new therapeutic target for type 2 diabetes.
Metformin is considered to be one of the most effective therapeutics for treating type 2 diabetes because it specifically reduces hepatic gluconeogenesis without increasing insulin secretion, inducing weight gain or posing a risk of hypoglycaemia 1, 2 . For over half a century, this agent has been prescribed to patients with type 2 diabetes worldwide, yet the underlying mechanism by which metformin inhibits hepatic gluconeogenesis remains unknown. Here we show that metformin non-competitively inhibits the redox shuttle enzyme mitochondrial glycerophosphate dehydrogenase, resulting in an altered hepatocellular redox state, reduced conversion of lactate and glycerol to glucose, and decreased hepatic gluconeogenesis. Acute and chronic low-dose metformin treatment effectively reduced endogenous glucose production, while increasing cytosolic redox and decreasing mitochondrial redox states. Antisense oligonucleotide knockdown of hepatic mitochondrial glycerophosphate dehydrogenase in rats resulted in a phenotype akin to chronic metformin treatment, and abrogated metformin-mediated increases in cytosolic redox state, decreases in plasma glucose concentrations, and inhibition of endogenous glucose production. These findings were replicated in whole-body mitochondrial glycerophosphate dehydrogenase knockout mice. These results have significant implications for understanding the mechanism of metformin's blood glucose lowering effects and provide a new therapeutic target for type 2 diabetes.
Initial investigations into metformin action found that this compound is a complex I inhibitor at millimolar concentrations 3, 4 . More recent studies suggested that metformin activates AMP-activated protein kinase (AMPK) through decreases in hepatic energy charge (increasing [AMP]:
[ADP] and/or [ADP]:[ATP] concentration ratios) 5, 6 or through the upstream AMPK kinase, LKB1, leading to reduction of gluconeogenic gene transcription [6] [7] [8] . This effect may, however, be due to sensitization of gluconeogenic transcription to insulin through AMPK-mediated decreases in hepatic lipid content 9, 10 .
In contrast to these findings, it has been suggested that metformin suppresses gluconeogenesis independently of AMPK, instead altering hepatic energy charge 11 and inducing allosteric inhibition of glycolytic enzymes or adenylate cyclase and glucagon-activated gluconeogenic transcription 12 . However, these hypotheses are inconsistent with findings that metformin does not alter hepatic adenine-nucleotide levels 13 .
Given these conflicting results, it is evident that the mechanisms by which guanide/biguanides exert their therapeutic effects remain to be explained. Variability in data on metformin action may arise because of differences in the dose of metformin administered in vivo ranging from 50 to 500 mg kg 21 , as well as observation of chronic versus acute responses to the drug.
In tracing the development of this drug class to the rapid-acting parent compound galegine (a mono-guanide), we considered that the acute glucose lowering effects reported might provide a model in which to investigate potential targets of action of the entire class. Within 20 min of intravenous infusion of galegine, plasma glucose and insulin concentrations decreased (Extended Data Fig. 1a, b) , and plasma lactate concentrations increased eightfold (Extended Data Fig. 1c ), independently of any changes in hepatic gluconeogenic gene expression (Extended Data Fig. 1d ). Galegine also increased total AMPKa2 activity (Extended Data Fig. 1e ). However, intravenous administration of the AMPK activator A-769662 failed to decrease plasma glucose concentrations or endogenous glucose production (EGP) (Extended Data Fig. 1f , g) despite comparable increases in AMPK activity 20 min after infusion (Extended Data Fig. 1h ). Thus although guanide/biguanide treatment may activate AMPK, acute AMPK activation is not sufficient to reduce EGP.
In considering other mechanisms for metformin action, we were struck by the consistent observation of a marked increase in plasma lactate concentrations in guanide/biguanide-treated animals. This increase could not be attributed to reduced activity of enzymes regulating pyruvate metabolism (Extended Data Fig. 2a ), as metformin, galegine and phenformin had no effect on pyruvate carboxylase, citrate synthase and alanine aminotransferase activity (Extended Data Fig. 2b-d ). We developed the alternative hypothesis that the striking increase in plasma lactate concentrations may be due to metformin-induced increases in the cytosolic redox state, known to manifest as an increased [lactate]:[pyruvate] ratio [14] [15] [16] . To verify this possibility we assessed the acute effects of metformin on fasting plasma glucose concentrations and rates of EGP at doses that are in the range used to treat patients with type 2 diabetes (20 mg kg 21 and 50 mg kg 21 ) in awake rats. As early as 30 min after administration, there was a marked reduction in fasting plasma glucose concentrations ( Fig. 1a ) and inhibition of EGP ( Fig. 1b and Extended Data Fig. 3a ). We measured the [lactate]:[pyruvate] and [b-hydroxybutyrate]:[acetoacetate] ratios as surrogates of the cytosolic and mitochondrial redox states, respectively [14] [15] [16] , and found that metformin elicited a significant increase in the cytosolic redox state and decrease in the mitochondrial redox state in both plasma and liver ( Fig. 1c-f and Extended Data Fig. 3b , c). Consistent with these findings, metformin treatment increased the liver [GSH]:[GSSG] ratio, reflecting an increase in the cytosolic redox state (Extended Data Fig. 3d ). These data support a mechanism for metformin's rapid effect on hepatic glucose production through alteration of the redox state. We also observed a trend towards increased plasma glycerol concentrations, suggesting inhibition of glycerol conversion to glucose (Fig. 1g Fig. 3j -l). There was no significant AMPK activation, as determined by relative levels of phosphorylated AMPK to total AMPK, and no change in the phosphorylation of the downstream target of AMPK, acetyl-coenzyme A carboxylase (ACC), although cyclic AMP response element binding protein (CREB) activation was observed as determined by the ratio of phosphorylated CREB to total CREB (Extended Data Fig. 3j , m-o).
Similar to acute metformin treatment, chronic metformin treatment lowered fasting plasma glucose concentrations and EGP ( Fig. 2a, b) . These changes were also associated with an increase in the plasma and cytosolic redox state and a decrease in the mitochondrial redox state ( Fig. 2c-f and Extended Data Fig. 4a ). Plasma glycerol concentrations were also higher in these animals ( Fig. 2g ). Similar to what was observed with acute metformin treatment, chronic metformin treatment did not alter hepatocellular energy charge (Extended Data Fig. 4b-e ), and there was only a slight reduction in liver [cAMP] (Extended Data Fig. 4f ). Protein expression of PEPCK-C and pyruvate carboxylase were also unchanged; however, AMPK was activated, ACC phosphorylation was increased and CREB activation was decreased (Extended Data Fig. 4g -l).
Given that acute and chronic metformin treatment increased the cytoplasmic redox state and decreased the mitochondrial redox state, we next considered that metformin may block one of the two main redox shuttle systems, the malate-aspartate and glycerophosphate shuttles [17] [18] [19] [20] . Guanides/biguanides had no effect on total malate-aspartate shuttle activity or on malate dehydrogenase and aspartate aminotransferase activities (Extended Data Fig. 2e -g).
We next examined the effect of metformin on the glycerophosphate shuttle 21 (Extended Data Fig. 5a ). Guanides/biguanides did not alter the activity of purified, recombinant cytosolic glycerophosphate dehydrogenase (cGPD) (Extended Data Fig. 5b ). In contrast, all guanides/biguanides inhibited mitochondrial GPD (mGPD) activity by 30-50% in rat mitochondrial lysates (Fig. 3a) . These findings are supported by our data showing 
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that metformin significantly inhibited mitochondrial respiration from glycerol-3-phosphate ( Fig. 3b ).
Given the impact of metformin on the cytosolic/mitochondrial redox state, we next examined whether we could influence the effectiveness of metformin by changing the cytosolic redox state by altering the extracellular [lactate]:[pyruvate] ratio 22, 23 . Consistent with this hypothesis we found that at lower [lactate]:[pyruvate], metformin and mGPD short interfering RNA (siRNA) treatment to knockdown expression of mGpd no longer significantly reduced glucose production from primary rat hepatocytes (Extended Data Fig. 6a ). This finding suggests that an augmented cytosolic redox state is central to metformin-mediated reduction in hepatic gluconeogenesis.
Inhibition of mGPD would prevent glycerol from contributing to gluconeogenic flux, as glycerol must be phosphorylated by glycerol kinase to glycerol-3-phosphate and converted to dihydroyacetone phosphate by mGPD to contribute to glucose production. Furthermore, inhibition of mGPD would halt the glycerophosphate shuttle and lead to accumulation of cytosolic NADH, which is unfavourable for conversion of lactate to pyruvate by lactate dehydrogenase (LDH). Consistent with this hypothesis, glucose production in hepatocytes from both lactate and glycerol was inhibited by metformin and mGpd knockdown. In contrast, metformin and mGpd knockdown had no effect on gluconeogenesis from dihydroxyacetone, alanine and pyruvate, substrates that enter gluconeogenesis without augmenting the cytosolic [NADH]:[NAD 1 ] ratio (Extended Data Fig. 6b , c). We also observed an increase in glycerol-3-phosphate concentrations in primary hepatocytes after metformin treatment and mGpd knockdown by siRNA, and specifically in liver after acute metformin treatment in vivo (Extended Data Fig. 6d, e ), consistent with metformin inhibition of mGPD activity. These data indicate that both acute and chronic metformin treatment inhibit mGPD, limiting lactate and glycerol contributions to hepatic gluconeogenesis.
To examine whether mGPD is the molecular target for metformin in vivo, we treated rats with antisense oligonucleotides (ASOs) to knock down hepatic mGpd and cGpd expression (Extended Data Fig. 7a, b ). As seen with metformin treatment, mGPD ASO treatment reduced plasma glucose concentrations, increased cytosolic redox state and decreased mitochondrial redox state. In contrast, cGPD ASO treatment had only a mild effect on cytosolic and mitochondrial redox state, did not alter plasma glucose levels and did not affect plasma lactate concentrations (Fig. 4a-c and Extended Data Fig. 7c ). These data are consistent with previous studies showing that knockout of the mGpd gene, but not cGpd, in mice results in a reduction in plasma glucose concentrations 24, 25 .
To investigate further whether mGPD is the primary target of metformin, we examined whether mGPD ASO treatment would abrogate the inhibitory effects of metformin on EGP. mGPD ASO treatment lowered plasma glucose concentrations and inhibited EGP. Moreover, mGPD ASO treatment abrogated the ability of metformin ability to decrease plasma glucose concentrations and inhibit EGP ( Fig. 4d, e ). mGPD-ASO-treated animals also had increased plasma [lactate]:[pyruvate] and decreased plasma [b-hydroxybutyrate]:[acetoacetate] ratios, whereas metformin had no extra effect on these parameters ( Fig. 4f, g ). As seen with metformin treatment, mGPD ASO increased the liver [GSH]:[GSSG] ratio, reflecting an increase in the cytosolic redox state (Extended Data Fig. 7d ). In contrast the energy charge in the liver was unaltered by mGpd knockdown (Extended Data Fig. 7e-h) , although a slight decrease in liver [cAMP] was observed (Extended Data Fig. 7i ). There was no appreciable effect of mGpd knockdown on hepatic PEPCK-C and pyruvate carboxylase expression, although AMPK activation, increased ACC phosphorylation and suppression of CREB activation were observed (Extended Data Fig. 7j-o) . Chronic metformin treatment of mGpd ASO knockdown rats also had no added effect on plasma glucose concentrations or EGP ( Fig. 4h , i). We next examined whether metformin's effects would be abrogated in a whole-body mGPD knockout mouse and found that these mice, similar to the mGPD-ASO-treated rats, had decreased fasting plasma glucose concentrations and decreased rates of EGP compared with wildtype littermates, and that the effects of acute metformin treatment on plasma glucose concentrations and EGP were also abrogated in mGPD knockout mice ( Fig. 4j, k) .
We further characterized the nature of metformin's effect on mGPD kinetics, and found that metformin inhibited isolated rat mGPD activity non-competitively with an inhibition constant (K i ) of approximately 38 mM (Extended Data Fig. 5c ). Metformin also inhibited purified recombinant human mGPD activity, showing non-competitive kinetics with K i , 55 mM ( Fig. 3c and Extended Data Fig. 5d ), and non-competitively inhibited activity of pure, Pediococcus a-glycerophosphate oxidase, a bacterial isoform of mammalian mGPD (Extended Data Fig. 5e ).
The glycerophosphate shuttle has an important role in the regulation of hepatic gluconeogenesis 26, 27 , the role of mGPD as a regulator of EGP being strongly supported by the finding that mGPD knockout mice have lowered plasma glucose concentrations 28 and are protected 
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from diet-induced hyperglycaemia 29 . We found that metformin inhibits mGPD activity in vitro with an approximate K i value close to the observed range of plasma metformin levels (10-40 mM) in patients treated with a normally prescribed dose of 1 g of metformin twice a day 11 . Our measurements of metformin concentrations in the plasma and liver of rats treated acutely with 50 mg kg 21 metformin gave us a peak average value of 74 mM and 100 mM, respectively, 30 min after administration (Extended Data Fig. 9 ). These pharmacokinetic data are consistent with the acute metformin-mediated inhibition of hepatic gluconeogenesis within a similar time frame and are consistent with the need to provide dosing of metformin twice a day to patients with type 2 diabetes for optimal plasma glucose lowering. Previous studies assessing metformin action in vivo have typically used metformin doses ranging from 250 mg kg 21 to 500 mg kg 21 , which are supra-pharmacological and result in plasma metformin concentrations greater than 1 mM (Extended Data Fig. 9 ). In this regard, although metformin inhibited mitochondrial respiration from glycerol-3-phosphate at micromolar concentrations, complex I respiration was affected only at metformin concentrations greater than 1 mM, which are not clinically relevant (Extended Data Fig. 2h ). The kinetics of metformin inhibition of mGPD was found to be noncompetitive, which raises the question of how this might be achieved. Computational analyses of the structure of the mGPD isoform, Streptococcus sp. a-glycerophosphate oxidase 30 , mutated in the flavin adenine dinucleotide (FAD) binding pocket to the sequence of the human mGPD, found that metformin shows favourable binding to the FADcontaining pocket (Extended Data Fig. 8a-c) . Based on these predictions, FAD, which is non-covalently associated with the enzyme, may dynamically slide in and out of the wider entrance of the tunnel-shaped pocket, and metformin may enter from the smaller end, preventing complete re-entry of FAD and inhibiting electron transfer. Although speculative, this model could explain how metformin could displace the flavin ring and inhibit enzymatic activity without necessarily invoking FAD turnover.
In summary, we have shown that metformin treatment of rats at doses that achieve comparable plasma metformin concentrations observed in patients with metformin-treated type 2 diabetes inhibits mGPD noncompetitively and modulates cytosolic and mitochondrial redox state, inducing an effective reduction in EGP. These results identify mGPD as one of the primary molecular targets by which guanides/biguanides inhibit hepatic gluconeogenesis, and provide a new therapeutic target for type 2 diabetes.
METHODS SUMMARY
Hepatocyte studies. Primary hepatocytes were isolated from 24-h-fasted Sprague-Dawley rats and treated with or without 100 mM metformin in DMEM supplemented with 10 mM substrate (glycerol at 100 mM). Glucose was measured using Genzyme Glucose-SL reagent. Animal studies. Studies were performed in 24-h-fasted, awake, unrestrained male Sprague-Dawley rats aged 9-12 weeks. Animals were randomly allocated to treatment groups before collection of any data and the studies were performed unblinded. Acute metformin was administered intravenously and chronic metformin was administered intraperitoneally at 50 mg kg 21 daily over 30 days. Continuous 1 mg kg 21 min 21 arterial infusion of [6,6-2 H 2 ]glucose tracer was administered to measure EGP. Plasma 
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glucose was measured on a YSI 2700 Biochemistry Analyzer. All other metabolites were measured using enzymatic methods. Whole-body mGPD knockout mouse embryos were a gift from M. J. MacDonald. Overnight-fasted mice were infused with [3-3 H]glucose at 0.05 mCi min 21 for 120 min to measure basal glucose turnover. Mice were restrained during the studies, and given acute metformin (50 mg kg 21 , intravenously) or saline. All animal studies were conducted with previous approval from Yale University Institutional Animal Care and Use Committee. ASO treatment studies. ASO treatment was administered at 37.5 mg kg 21 twice weekly for 4 weeks by intraperitoneal injection. ASO treatment knocked down mGPD messenger RNA (mRNA) and protein only in the liver (Extended Data Fig. 10 ). Enzyme assays. mGPD activity in rat liver mitochondrial lysate was measured using cytochrome c as the electron acceptor and measuring gain of absorbance at 550 nm. Activities of rat mGPD isolated from rat mitochondrial lysate using anti-GPD2 antibody K-14, and human mGPD overexpressed in HEK 293 cells from an Origene vector, were measured using 2,6-dichloroindophenol (DCIP) and measuring loss of absorbance at 600 nm. Kinetic measurements were made using a Flexstation 3 Benchtop Multi-Mode Microplate Reader (Molecular Devices). Oxygen consumption. Studies were performed on a Seahorse Bioscience XF24 Analyzer.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Hepatocyte studies. Primary hepatocytes were freshly isolated by collagenase digestion of livers from hepatic glycogen-deplete, 24-h-fasted Sprague-Dawley rats, and plated on collagen-coated six-well plates. Cells were cultured overnight in recovery media (DMEM supplemented with 4.5 g ml 21 glucose, 1 nM dexamethasone, insulin, 10% FBS, 1% penicillin-streptomycin, 10 mM HEPES and 3.7 mg ml 21 sodium bicarbonate). Cells were then pre-incubated for 2 h in no-glucose DMEM supplemented with 10 mM HEPES and 3.7 mg ml 21 sodium bicarbonate with or without 100 mM metformin, followed by a 2-h incubation in no-glucose DMEM supplemented with 10 mM substrate (except glycerol, which was added at 100 mM). Cells were treated with 20 nM siRNA in recovery media overnight: siRNA transfection was performed using RNAiFect Transfection reagent (Qiagen, 301605). siRNA sequences used were control (Sigma Aldrich Mission siRNA Universal Negative Control, SIC001) and mGPD (Sigma Aldrich, SASI_Rn02_00260086, sequence start: 1395, National Center for Biotechnology Information (NCBI) gene NM_012736). siRNA did not induce cytotoxicity, as determined by trypan blue exclusion, CyQuant Assay (Life Technologies, C35011) and cytochrome c release into the cytosolic fraction (Extended Data Fig. 6f-h) . Glucose in the media was measured using Genzyme Glucose-SL reagent, and glucose production was normalized to total protein levels as measured by Bradford assay. Animal studies. Male Sprague-Dawley rats were acquired from Charles River, and were administered regular chow and water ad libitum. Rats were housed individually on a 12:12-h light:dark cycle. Arterial lines were surgically implanted into the carotid artery and venous lines into the jugular vein of rats for the studies. All animal studies included 6-10 rats per group, aged 9-12 weeks and weighed 300-450 g at the time of study. Animals were randomly allocated to treatment groups before collection of any data (for example, weight) or surgical procedures and the studies were performed unblinded. Sample sizes were selected to detect moderate to large (.20%) differences. All studies were performed in awake, unrestrained animals. Acute metformin was administered intravenously in 0.9% saline at 20, 50, 100 and 250 mg kg 21 and chronic metformin was administered intraperitoneally at 50 mg kg 21 daily over 30 days. Galegine solutions were prepared in normal saline and infused intravenously at 25 mg kg 21 h 21 after a 5 min 250 mg kg 21 h 21 prime. Rats were fasted for 24 h before studies were conducted. Rats were anaesthetized by intravenous pentobarbital. A continuous arterial infusion of [6,6-2 H 2 ]glucose tracer at a rate of 1 mg kg 21 min 21 was administered throughout the study (after a 5 min, 3 mg kg 21 min 21 prime) to measure EGP. Plasma glucose enrichment was measured by derivatizing deproteinized plasma samples with acetic anhydride and pyridine, and 2 H enrichment was measured by gas chromatography mass spectrometry as previously described 1 . Plasma glucose was measured on a YSI 2700 Biochemistry Analyzer from sampled venous blood. All other plasma metabolites were measured from sampled venous blood using enzymatic methods and monitoring changes in NADH absorbance at 340 nm. Liver metabolites were measured from PCA-extracted samples immediately after collection. High-energy intermediates were measured from liver tissue extracted in a methanol, ammonium acetate based buffer by liquid chromatographytandem mass spectrometry, and values were normalized to an added internal standard, D 4 -taurine. Tissues were rapidly acquired and freeze-clamped in situ within 10 s of anaesthetizing the animals (delays in tissue processing contribute extensive errors to [ATP]:[ADP] and [ATP]:
[AMP] ratios which should be approximately 2:1 and 10:1, respectively, in normal tissues 31 ). Whole-body mGPD knockout mouse embryos were a gift from M. J. MacDonald. Mice were bred and genotyped following standard protocols. Catheters were surgically implanted into the jugular vein of mice 5-7 days before performing glucose infusion studies as previously described 32 . Mice were fasted overnight before the studies, and infused with [3-3 H]glucose at a rate of 0.05 mCi min 21 for 120 min to measure basal glucose turnover. Mice were restrained during the studies, and given an acute dose of metformin (50 mg kg 21 , intravenously) or saline control.
All studies involving animals were conducted with previous approval from Yale University Institutional Animal Care and Use Committee in compliance with the ethical standards outlined by the Committee. ASO treatment studies. ASO treatment was administered at a dosing schedule of 37.5 mg kg 21 twice weekly for 4 weeks by intraperitoneal injection, and for 6 weeks at the same dose for the chronic metformin with mGPD ASO treatment study. ASOs used in vivo were selected from a pool of approximately 80 ASOs that were prescreened in vitro for target efficacy. The most active compounds were further screened in vivo to select the compounds used in this study. The ASO identification numbers and sequences are as follows: control ASO used in all studies, 59-CCTTCCCTGAA GGTTCCTCC-39 (ISIS 141923); cGPD ASO 1, 59-GTCCACCTCTTGTACCACG G-39 (ISIS 594525); cGPD ASO 2, 59-GTGGTGTCACACGCTTCTGC-39 (594536); mGPD ASO 1, 59-GGCAGCTACAATGGCCACTA-39 (594990); mGPD ASO 2, 59-AGCAAGGATTTTTCTGGCAA-39 (594995). mGPD ASO 2 and cGPD ASO 1 were used for all studies after screening. ASOs were re-suspended and delivered in 0.9% saline. ASO treatment did not induce liver toxicity, as measured by plasma AST/ALT for the mGPD versus cGPD ASO study and the mGPD with acute metformin study, and mGPD ASO treatment did not alter body weight (Extended Data Fig. 10a-c) . ASO treatment caused robust, targeted knockdown of mGPD mRNA and protein only in the liver, with only a slight decrease in mRNA in the white adipose tissue (WAT; Extended Data Fig. 10d ), and a minimal yet insignificant decrease in mGPD protein levels in the white adipose tissue and the pancreas. There was no effect on either mRNA transcript or protein levels in the muscle, brown adipose tissue or kidney (Extended Data Fig. 10e-k) . Galegine synthesis. Galegine was prepared according to the procedure reported in ref. 33. AMPK activity assay. Freeze-clamped livers were ground and lysed in lysis buffer (50 mM Tris-HCl pH 7.5, 50 mM NaF, 5 mM NaPPi, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothrietol, 1 mM benzamidine, 1 mM phenylmethanesulphonyl fluoride, 10% v/v glycerol, 1% v/v Triton X-100). Liver homogenates were centrifuged at 20,800g for 15 min at 4 uC and protein concentration was measured by Bradford assay. AMPK-a2 was immunoprecipitated overnight from cell lysates containing 1 mg protein using 10 ml AMPK-a2 antibody (Santa Cruz Biotechnology, sc-19131). Liver AMPK-a2 activity was determined by the incorporation of [ 32 P]ATP into a synthetic peptide containing the AMARA sequence. Real-time quantitative PCR with reverse transcription. RNA was isolated using a Qiagen RNAeasy kit (Qiagen). mRNA was reverse transcribed to cDNA using MuLV reverse transcriptase (New England Bio Labs). The abundance of transcripts was assessed by real-time PCR on a 7500 Fast Real-Time PCR System (Applied Biosystems). Each run was evaluated in duplicate for both the gene of interest and actin as a control. The expression data for the gene of interest and actin were normalized for the efficiency of amplification determined by the standard curve included for each data acquisition. Primer sequences used were as follows: mGPD forward, 59-AGGAGGCAAAGATTGGAGCC-39; mGPD reverse, 59-TCTGACACAAGA CGCACTCC-39; cGPD forward, 59-AAGACATCGGGGGCAGAAAG-39; cGPD reverse, 59-GGCCCTCGTCTATCCCCTTA-39; actin forward, 59-CCAGATCAT GTTTGAGACCTTC-39; actin reverse, 59-CATGAGGTAGTCTGTCAGGTCC-39. Enzyme assays. Enzyme assays measuring mGPD activity using rat liver mitochondrial lysate preparation were performed using cytochrome c as the electron acceptor and measuring gain of absorbance at 550 nm (reaction buffer consisted of 10 mM Tris-HCl, 50 mM cytochrome c, 25 mM sodium azide, 1 mM EDTA, 50 mM KCl; buffers were bubbled with N 2 gas before assay; lysates were pre-incubated in buffer with or without treatment for 10 min; the reaction was conducted at 38 uC). Mitochondria were isolated less than 3 h before conducting activity assays from fresh rat livers. Briefly, rat liver was homogenized using a glass dounce homogenizer in icecold isolation buffer (210 mM sucrose, 660 mM mannitol, 30 mM KH 2 PO 4 , 15 mM MgCl 2 -6H 2 O, 3 mM EGTA and 75 mM MOPS). Mitochondria were separated from total homogenate by differential centrifugation. Rat mGPD was isolated from rat mitochondrial lysate by immunoprecipitation by anti-GPD2 antibody K-14 (Santa Cruz Biotechnology, sc-161680) at a ratio of 1 mg lysate protein per 10 ml antibody, overnight, at 4 uC. Activity was measured using 2,6-dichloroindophenol (DCIP) as the electron acceptor and measuring loss of absorbance at 600 nm (reaction buffer consisted of 50 mM KH 2 PO 4 , 95 mM DCIP; reaction conducted at 38 uC; mitochondrial lysate pre-incubated in buffer with or without metformin for 10 min). Human mGPD tagged with Myc-DDK was overexpressed in HEK 293 cells (ATCC CRL-1573) from a pre-designed vector available from Origene. Recombinant human mGPD was isolated by immunoprecipitation from the cell lysates using an anti-DDK antibody (Origene) at 10 ml antibody per 1 mg lysate protein, and activity was measured using DCIP as the electron acceptor. Recombinant, purified Pediococcus sp. a-glycerophosphate oxidase was obtained from Sigma and activity was determined by indirectly detecting peroxide production by oxidation of o-phenylenediamine in the presence of phenol and measuring increase in absorbance at 450 nm. Michaelis-Menten, Eadie-Hofstee and Lineweaver-Burk plots were used to determine the kinetics of inhibition. Kinetic measurements used a Flexstation 3 Benchtop Multi-Mode Microplate Reader (Molecular Devices). Western blotting. Liver lysates were made by homogenizing pulverized, freezeclamped liver tissue in lysis buffer (50 mM Tris-HCl pH 7.4, 1 mM EGTA, 150 mM NaCl, 5 mM MgCl 2, 1% NP-40) with added cOmplete protease inhibitor tablet (Roche) per 50 ml buffer. SDS samples were prepared by adding 23 SDS sample buffer (20% glycerol, 120 mM Tris-HCl pH 6.8, 4% SDS, 0.02% bromophenol blue, 4% b-mercaptoethanol) to one volume of lysate and boiling at 95 uC for 5 min. Samples were run on Novex 4-12% Tris-Glycine gels (Invitrogen) and gels were transferred to PVDF membranes by semi-dry transfer. Antibodies used to determine protein expression were as follows: PEPCK-C H-300 (Santa Cruz Biotechnology, sc-32879), PCB H-2 (Santa Cruz Biotechnology, sc-271493), Phospho-CREB Ser133 87G3 (Cell Signaling, 9198), CREB 48H2 (Cell Signaling, 9197), Phospho-AMPKa Thr172 40H9 (Cell Signaling, 2535), AMPKa (Cell Signaling, 2532), GAPDH D16H11 XP (Cell Signaling, 5174) and anti-GPD2 K-14 (Santa Cruz Biotechnology, sc-161680).
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Molecular docking and binding simulation. Molecular docking simulations used the program Glide (Schrodinger), with a modified version of the crystal structure of a-glycerophosphate oxidase from Streptococcus sp. (Protein Data Bank 2RGH) as the target enzyme. Sequence alignments with human mitochondrial glycerol-3phosphate dehydrogenase (hG3PD, NCBI reference sequence NM_000408.4) were used to mutate the FAD binding site coordinates of 2RGH to the corresponding hG3PD sequence. As a positive control, a docking simulation of FAD to this target protein yielded a result essentially identical to the actual FAD position observed in the 2RGH structure. Subsequent docking simulations were conducted using metformin, buformin, phenformin and galegine. Oxygen consumption. Mitochondria were prepared immediately before each study on a Seahorse Bioscience XF24 Analyzer. Liver was rapidly excised from an overnight-fasted rat anaesthetized under isoflurane. Liver was then homogenized in mitochondrial assay solution (70 mM sucrose, 220 mM mannitol, 5 mM KH 2 PO 4 , 5 mM MgCl 2 , 2 mM HEPES, 1 mM EGTA, 0.2% BSA). Mitochondria were purified by differential centrifugation and the mitochondrial pellet was used for respiration studies in mitochondrial assay solution without BSA. All reagents were diluted in mitochondrial assay solution without BSA and loaded into the ports of the flux plate (port A: 10 mM pyruvate, 2.5 mM glutamate, 2,5 mM malate; port B: 2 mM rotenone; port C: 5 mM succinate or 10 mM glycerol-3-phosphate; port D: 1 mg ml 21 oligomycin). Statistical analysis. All data are expressed as mean 6 s.e.m. P values less than 0.05 were considered statistically significant differences as determined by unpaired two-tailed Student's t-test or ANOVA. Data shown are representative of repeated experiments performed as indicated; where not indicated, a single experiment was performed. All replicates are biological replicates unless otherwise indicated. 
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